In recent years, the treatment of immune checkpoint blockers (ICBs), such as Nabuliumab (anti-programmed cell death protein 1 [PD-1]) and Attillizumab (anti-programmed cell death ligand-1 [PD-L1]), has revolutionized the treatment landscape of advanced HCC [76]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.